4268 Federal Register / Vol. 80, No. 17 / Tuesday, January 27, 2015 / Notices 

numbers above each band 

representing the fold change human 

prostate cancer cell lines; the numbers 

above each band representing the fold 

change in expression relative to the 

DMSO control also were falsified for 

p-ACLY (LNCaP cell line) and p-Akt 

(PC3 and LNCaP cell lines) compared 

to the values provided to the 

Respondent 

• falsified Figure 4D by substituting 

bands for p-ACLY for those provided 

to him to allow Respondent to claim 

that Z-Gug significantly inhibited 

phosphorylation of ACLY in lysates of 

prostate tumors obtained from mice, 

when the original data showed no 

effect 

• falsified Figures 5C and 5D to show 

that treatment of PC3 and LNCaP cells 

with Z-Gug alone and with Z-Gug 

plus si-RNA targets to ACLY 

stimulated Caspase 3/7 activity, when 

the original data provided to him 

showed no significant effect of either 

treatment in PC3 cells and no effect of 

Z-Gug alone in LNCaP cells 

• falsified Figures 6G and 6H; these 

figures purported to show that Nacetyl-L-cysteine (NAC), an inhibitor 

of reactive oxygen species (ROS), 

reversed the inhibition of Akt 

phosphorylation caused by Z-Gug in 

PC3 cells (Figure 6G) and LNCaP cells 

(Figure 6G) when no Akt data for this 

protocol was available to the 

Respondent; Respondent admitted to 

falsifying Figure 6G 

• falsified Figures S2B and S3B by 

altering data provided to him; these 

experiments are complementary to 

those shown in Figures 5C and 5D, 

except that the effect of Z-Gug and Zgug plus si-RNA on Caspase 3/7 

activity utilized on si-RNA was 

directed to Akt activity. The original 

data showed no significant effect of 

either treatment in PC3 cells and no 

effect of Z-Gug on LNCaP cells, while 

both treatments were claimed to be 

significant inducers of caspase 

activity in both cell lines in the 

published figures. 

Dr. Xiao has entered into a Voluntary 

Settlement Agreement (Agreement) and 

has voluntarily agreed for a period of 

three (3) years, beginning on December 

23, 2014: 

(1) To have his research supervised; 

Respondent agreed to ensure that prior 

to the submission of an application for 

U.S. Public Health Service (PHS) 

support for a research project on which 

the Respondent’s participation is 

proposed and prior to Respondent’s 

participation in any capacity on PHSsupported research, the institution 

employing him must submit a plan for 

supervision of his duties to ORI for 

approval; the plan for supervision must 

be designed to ensure the scientific 

integrity of Respondent’s research 

contribution; Respondent agreed that he 

will not participate in any PHSsupported research until such a 

supervision plan is submitted to and 

approved by ORI; Respondent agreed to 

maintain responsibility for compliance 

with the agreed upon plan for 

supervision; 

(2) that any institution employing him 

must submit, in conjunction with each 

application for PHS funds, or report, 

manuscript, or abstract involving PHSsupported research in which 

Respondent is involved, a certification 

to ORI that the data provided by 

Respondent are based on actual 

experiments or are otherwise 

legitimately derived and that the data, 

procedures, and methodology are 

accurately reported in the application, 

report, manuscript, or abstract; and 

(3) to exclude himself voluntarily 

from serving in any advisory capacity to 

PHS including, but not limited to, 

service on any PHS advisory committee, 

board, and/or peer review committee, or 

as a consultant. 

FOR FURTHER INFORMATION CONTACT: 

Acting Director, Office of Research 

Integrity, 1101 Wootton Parkway, Suite 

750, Rockville, MD 20852, (240) 453– 

8200. 

Donald Wright, 

Acting Director, Office of Research Integrity. 

[FR Doc. 2015–01427 Filed 1–26–15; 8:45 am] 

BILLING CODE 4150–31–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Notice of Interest Rate on Overdue 

Debts 

Section 30.18 of the Department of 

Health and Human Services’ claims 

collection regulations (45 CFR part 30) 

provides that the Secretary shall charge 

an annual rate of interest, which is 

determined and fixed by the Secretary 

of the Treasury after considering private 

consumer rates of interest on the date 

that the Department of Health and 

Human Services becomes entitled to 

recovery. The rate cannot be lower than 

the Department of Treasury’s current 

value of funds rate or the applicable rate 

determined from the ‘‘Schedule of 

Certified Interest Rates with Range of 

Maturities’’ unless the Secretary waives 

interest in whole or part, or a different 

rate is prescribed by statute, contract, or 

repayment agreement. The Secretary of 

the Treasury may revise this rate 

quarterly. The Department of Health and 

Human Services publishes this rate in 

the Federal Register. 

The current rate of 101⁄2%, as fixed by 

the Secretary of the Treasury, is certified 

for the quarter ended December 31, 

2014. This rate is based on the Interest 

Rates for Specific Legislation, ‘‘National 

Health Services Corps Scholarship 

Program (42 U.S.C. 250(B)(1)(A))’’ and 

‘‘National Research Service Award 

Program (42 U.S.C. 288(c)(4)(B)).’’ This 

interest rate will be applied to overdue 

debt until the Department of Health and 

Human Services publishes a revision. 

Dated: January 15, 2015. 

David C. Horn, 

Director, Office of Financial Policy and 

Reporting. 

[FR Doc. 2015–01429 Filed 1–26–15; 8:45 am] 

BILLING CODE 4150–04–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Meeting of the Presidential Advisory 

Council on HIV/AIDS 

AGENCY: Office of the Assistant 

Secretary for Health, Office of the 

Secretary, Department of Health and 

Human Services. 

ACTION: Notice. 

SUMMARY: As stipulated by the Federal 

Advisory Committee Act, the U.S. 

Department of Health and Human 

Service (DHHS) is hereby giving notice 

that the Presidential Advisory Council 

on HIV/AIDS (PACHA) will hold a 

meeting to discuss essential health 

benefits and provider networks, the 

integration of the Affordable Care Act 

(ACA) qualified health plan and the 

Ryan White Program; an update on the 

National HIV/AIDS Strategy; and a 

discussion on surveillance data. The 

meeting will be open to the public. 

DATES: The meeting will be held on 

February 12, 2015, from 9 a.m. to 

approximately 5 p.m. (ET) and February 

13, 2015, from 9:30 a.m. to 

approximately 12:30 p.m. (ET). 

ADDRESSES: Renaissance Washington 

DC, Downtown Hotel, 999 Ninth Street 

NW., Washington, DC 20001. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Caroline Talev, Public Health Analyst, 

Presidential Advisory Council on HIV/ 

AIDS, U.S. Department of Health and 

Human Services, 200 Independence 

Avenue SW., Room 443H, Washington, 

DC 20201; (202) 205–1178. More 

detailed information about PACHA can 

be obtained by accessing the PACHA 

Web page on the AIDS.Gov Web site at 

www.aids.gov/pacha. 


asabaliauskas on DSK5VPTVN1PROD with NOTICES